IDEXX Laboratories Inc

Chart & Performance

D1W1MN

P/E

40.08

P/S

9.25

EPS

10.32

Div Yield, %

0.00%

Shrs. gr., 5y

-1.04%

Rev. gr., 5y

10.59%

Revenues

3.66b

+8.72%

Net income

845m

+24.44%

CFO

907m

+66.95%

Earnings

Feb 03, 2025

Profile

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

URL

https://www.idexx.com/

IPO date

Jun 21, 1991

Employees

11,000

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	3,660,953 8.72%	3,367,324 4.73%	3,215,360 18.79%
Cost of revenue	2,563,825	2,468,559	2,283,332
Unusual Expense (Income)
NOPBT	1,097,128	898,765	932,028
NOPBT Margin	29.97%	26.69%	28.99%
Operating Taxes	216,134	180,883	157,810
Tax Rate	19.70%	20.13%	16.93%
NOPAT	880,994	717,882	774,218
Net income	845,042 24.44%	679,089 -8.83%	744,845 28.03%
Dividends
Dividend yield
Proceeds from repurchase of equity	(71,920)	(794,570)	(715,774)
BB yield	0.15%	2.30%	1.26%
Debt
Debt current	344,799	653,982	148,496
Long-term debt	842,027	816,051	882,513
Deferred revenue	28,533	30,862	41,174
Other long-term liabilities	65,526	168,826	158,318
Net debt	676,701	1,301,987	873,207
Cash flow
Cash from operating activities	906,510	542,984	755,546
CAPEX	(133,631)	(148,838)	(119,549)
Cash from investing activities	(125,254)	(195,350)	(292,967)
Cash from financing activities	(441,996)	(370,936)	(697,414)
FCF	598,775	445,083	691,637
Balance
Cash	453,932	112,546	144,454
Long term investments	56,193	55,500	13,348
Excess cash	327,077
Stockholders' equity	4,384,116	3,532,452	2,877,644
Invested Capital	2,318,865	2,108,247	1,770,580
ROIC	39.80%	37.02%	48.13%
ROCE	41.35%	42.47%	52.38%
EV
Common stock shares outstanding	83,978	84,600	86,572
Price	555.05 36.06%	407.96 -38.04%	658.46 31.73%
Market cap	46,611,989 35.05%	34,513,416 -39.45%	57,004,199 31.50%
EV	47,288,690	35,815,403	57,877,406
EBITDA	1,212,036	1,010,665	1,036,624
EV/EBITDA	39.02	35.44	55.83
Interest	41,581	38,793	29,374
Interest/NOPBT	3.79%	4.32%	3.15%